AtriCure, Inc.

287 articles with AtriCure, Inc.

• AtriCure to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/12/2021

  AtriCure, Inc., a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, announced that the company will be participating in the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference.

• AtriCure Reports Third Quarter 2021 Financial Results

  11/3/2021

  AtriCure, Inc. today announced third quarter 2021 financial results.

• AtriCure to Participate in Upcoming Investor Conferences - Oct 26, 2021

  10/26/2021

  AtriCure, Inc., a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, announced that the company will be participating in upcoming investor conferences.

• AtriCure to Announce Third Quarter 2021 Financial Results

  10/5/2021

  AtriCure, Inc. today announced that it will release third quarter 2021 financial results on Wednesday, November 3, 2021.

• AtriCure to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference

  8/31/2021

  AtriCure to Participate at the Morgan Stanley 19 th Annual Global Healthcare Conference

• AtriCure Reports Second Quarter 2021 Financial Results

  8/4/2021

  AtriCure, Inc., a leading innovator in treatments for atrial fibrillation and left atrial appendage management, announced second quarter 2021 financial results.

• AtriCure to Participate at the Canaccord 41st Annual Growth Conference

  7/30/2021

  AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41st Annual Growth Conference.

• AtriCure to Announce Second Quarter 2021 Financial Results

  7/7/2021

  AtriCure, Inc. today announced that it will release second quarter 2021 financial results on Wednesday, August 4, 2021.

• AtriCure’s EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients

  4/29/2021

  AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced U.S. Food and Drug Administration (FDA) approval of the EPi-Sense® System to treat patients diagnosed with long-standing persistent Afib

• AtriCure Reports First Quarter 2021 Financial Results

  4/27/2021

  AtriCure, Inc., a leading innovator in treatments for atrial fibrillation and left atrial appendage management, announced first quarter 2021 financial results.

• AtriCure Names B. Kristine Johnson Board Chair

  4/8/2021

  AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that B. Kristine (Kris) Johnson has been named Board Chair.

• AtriCure to Announce First Quarter 2021 Financial Results

  4/6/2021

  AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its first quarter 2021 financial results on Tuesday, April 27, 2021. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Tuesday, April 27, 2021 to discuss its first quarter 2021 financial results.

• AtriCure to Participate at the Oppenheimer 31st Annual Healthcare Conference

  3/2/2021

  AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Oppenheimer 31st Annual Healthcare Conference.

• AtriCure Reports Fourth Quarter 2020 and Full Year 2020 Financial Results

  2/23/2021

  AtriCure, Inc., a leading innovator in treatments for atrial fibrillation and left atrial appendage management, announced fourth quarter 2020 and full year 2020 financial results.

• AtriCure to Participate at the SVB Leerink 10th Annual Global Healthcare Conference

  2/10/2021

  AtriCure to Participate at the SVB Leerink 10 th Annual Global Healthcare Conference

• AtriCure to Announce Fourth Quarter and Full Year 2020 Financial Results

  2/2/2021

  AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2020 financial results on Tuesday, February 23, 2021.

• AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2020

  1/11/2021

  AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced preliminary financial results for the fourth quarter and full year 2020.

• AtriCure Announces Labeling Expansion for Cryo Nerve Block Therapy

  1/4/2021

  Expansion includes adolescent patients, as young as 12 years of age, who can benefit from cryo nerve block therapy during surgical procedures involving the chest wall.

• AtriCure to Participate in the 39th Annual J.P. Morgan Healthcare Conference

  12/14/2020

  AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming 39th Annual J.P. Morgan Healthcare Conference being held virtually.

• AtriCure to Participate in Upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference

  11/19/2020

  AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will participate in the upcoming Piper Sandler 32 nd Annual Virtual Healthcare Conference. Conference Dates: Tuesday, December 1 to Thursday